CRH Medical Corp (CRH) to Post FY2018 Earnings of $0.05 Per Share, Clarus Securities Forecasts

CRH Medical Corp (TSE:CRH) – Analysts at Clarus Securities issued their FY2018 earnings per share (EPS) estimates for CRH Medical in a research note issued on Tuesday, according to Zacks Investment Research. Clarus Securities analyst N. Atkinson forecasts that the company will post earnings of $0.05 per share for the year. Clarus Securities also issued estimates for CRH Medical’s FY2019 earnings at $0.17 EPS.

Several other brokerages have also issued reports on CRH. National Bank Financial raised their target price on CRH Medical from C$4.25 to C$4.50 and gave the stock an “outperform” rating in a research report on Tuesday, March 6th. TD Securities increased their price target on CRH Medical from C$2.50 to C$3.50 and gave the stock a “hold” rating in a report on Wednesday, March 7th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. CRH Medical has an average rating of “Buy” and an average target price of C$4.19.

CRH Medical (TSE:CRH) opened at C$3.54 on Thursday. The stock has a market capitalization of $265.06, a price-to-earnings ratio of 32.18 and a beta of 0.71. CRH Medical has a 12-month low of C$1.86 and a 12-month high of C$12.35.

ILLEGAL ACTIVITY NOTICE: “CRH Medical Corp (CRH) to Post FY2018 Earnings of $0.05 Per Share, Clarus Securities Forecasts” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at

About CRH Medical

CRH Medical Corporation provides products and services to physicians for the treatment of gastrointestinal diseases in the United States. It offers anesthesia services for patients undergoing endoscopic procedures; and CRH O'Regan System, a single use, disposable, and hemorrhoid banding technology for treating hemorrhoid grades I?IV.

Get a free copy of the Zacks research report on CRH Medical (CRH)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with's FREE daily email newsletter.

Leave a Reply